Dasatinib re-challenge feasible as 2nd attempt at TKI discontinuation

Print Friendly, PDF & Email


Dennis Kim, MD
Photo by Jen Smith
Preliminary trial results suggest re-treatment with dasatinib is feasible and safe for a second attempt at tyrosine kinase inhibitor (TKI) discontinuation in chronic myeloid leukemia (CML) patients who fail to achieve treatment-free remission (TFR) after discontinuing imatinib. However, investigators reported the rate of second TFR (TFR2) was 21%... [Read Article]
Print Friendly, PDF & Email

Optimizing use of TKIs in CML

Print Friendly, PDF & Email


Hagop Kantarjian, MD
Long-term efficacy and toxicity should inform decisions about tyrosine kinase inhibitors (TKIs) in chronic myeloid leukemia (CML), according to the keynote presenter at Leukemia and Lymphoma: Europe and the USA, Linking Knowledge and Practice. Studies have indicated that long-term survival rates are similar whether CML patients receive frontline treatment with imatinib... [Read Article]
Print Friendly, PDF & Email

AMP publishes report on DNA variants in CMNs

Print Friendly, PDF & Email


Polycythemia vera
Image courtesy of AFIP
A new report addresses the clinical relevance of DNA variants in chronic myeloid neoplasms (CMNs). The report is intended to aid clinical laboratory professionals with the management of most CMNs and the development of high-throughput pan-myeloid sequencing testing panels. The authors list 34 genes they consider “critical” for sequencing... [Read Article]
Print Friendly, PDF & Email

Familial risk of myeloid malignancies

Print Friendly, PDF & Email


Three generations of
women in a family
A large study has revealed “the strongest evidence yet” supporting genetic susceptibility to myeloid malignancies, according to a researcher. The study showed that first-degree relatives of patients with myeloid malignancies had double the risk of developing a myeloid malignancy themselves, when compared to the general population. The researchers... [Read Article]
Print Friendly, PDF & Email

CHMP backs approval of dasatinib for kids

Print Friendly, PDF & Email


CML cells
Image by Difu Wu
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended changes to the marketing authorization for dasatinib (Sprycel). The CHMP is recommending approval for dasatinib as a treatment for pediatric patients with newly diagnosed, Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase... [Read Article]
Print Friendly, PDF & Email

Agent exhibits activity in leukemias, MDS

Print Friendly, PDF & Email


AML cells
The experimental agent prexigebersen (formerly BP1001) was considered well-tolerated and demonstrated early evidence of activity against relapsed/refractory hematologic disorders in a phase 1/1b trial. The drug reduced blasts in the bone marrow and peripheral blood for patients with acute myeloid leukemia (AML), chronic myeloid leukemia (CML), and myelodysplastic syndrome (MDS). When given... [Read Article]
Print Friendly, PDF & Email

FDA approves nilotinib for kids with CML

Print Friendly, PDF & Email


Nilotinib (Tasigna)
Photo from Novartis
The US Food and Drug Administration (FDA) has expanded the approved indication for nilotinib (Tasigna®) to include the treatment of children. The drug is now approved to treat patients age 1 and older who have newly diagnosed Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in the chronic phase. Nilotinib... [Read Article]
Print Friendly, PDF & Email